Gilead Is UBS's Top Biotechnology Pick, Roden Says

Gilead Is UBS's Top Biotechnology Pick, Roden Says Play

Sept. 10 (Bloomberg) -- Matthew Roden, senior biotechnology analyst at UBS Securities, talks with Bloomberg Industries senior health-care analyst Andrew Berens and Bloomberg First Word health-care journalist Sasha Damouni about the Hepatitis C marketplace including drug development and potential mergers and acquisitions in the space. (Source: Bloomberg)

  • On Air Now

    First Up with Angie Lau Watch Now

  • Next

    On the Move with Rishaad Salamat

blog comments powered by Disqus